EGFR and head and neck squamous cell carcinoma: Similarly, a Phase II trial demonstrated that afatinib monotherapy was effective in recurrent or metastatic HNSCC resistant to platinum-based treatments, suggesting that sequential ErbB inhibition may benefit certain patient subgroups [85,92].